ALK-negative Anaplastic Large Cell Lymphoma
Showing 1 - 3 of 3
Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)
Completed
- Peripheral T Cell Lymphoma
- +18 more
-
Vancouver, British Columbia, Canada
- +29 more
Apr 29, 2022
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell
Unknown status
- Peripheral T-Cell Lymphoma, Not Otherwise Specified
- +5 more
- CEOP/IVE/GDP chemotherapy regimen
- CEOP chemotherapy regimen for 6 cycles
-
Fuzhou, Fujian, China
- +3 more
Mar 7, 2020
ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified, Angioimmunoblastic T Cell
Unknown status
- ALK-negative Anaplastic Large Cell Lymphoma
- +5 more
- Cyclophosphamide 750mg/m2
- +8 more
-
Shanghai, Shanghai, ChinaRuijin hospital
Nov 10, 2017